The doctrine of equivalents in the medtech arena
The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.
- A stricter interpretation: the EPO and antibodies 27-10-2020
- COVID-19: Protection of IP for AI tools 01-09-2020
- How patents for transgenic mice got caught in a sufficiency trap 16-07-2020
- EPO’s G3/19: no turning back? 02-07-2020
- Analysis: Kymab’s ‘patent bargain’ clarification and why it matters 25-06-2020
Latest biotechnology news
India approves COVID-19 vaccines ahead of huge rollout
05-01-2021
India has granted emergency approval to COVID-19 vaccines developed by AstraZeneca and Oxford University and one from the state-run institute Bharat Biotech, ahead of a huge immunisation drive that is planned to begin this week.
